# POU2F2

Source: https://onco.cc/targets/pou2f2/  
OnCo record `pou2f2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

POU2F2 (POU domain, class 2, transcription factor 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.

## Summary

Transcription factor that specifically binds to the octamer motif (5'-ATTTGCAT-3'). Regulates IL6 expression in B cells with POU2AF1. Regulates transcription in a number of tissues in addition to activating immunoglobulin gene expression.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 4 cohorts (3 activating, 1 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: POU class 2 homeobox 2; POU domain, class 2, transcription factor 2; OCT2; OTF2
- Tags: cancer-genes-wave
- Symbol: POU2F2
- Class: transcription
- Biology: Transcription factor that specifically binds to the octamer motif (5'-ATTTGCAT-3'). Regulates IL6 expression in B cells with POU2AF1. Regulates transcription in a number of tissues in addition to activating immunoglobulin gene expression. Modulates transcription transactivation by NR3C1, AR and PGR. Activates the U2 small nuclear RNA (snRNA) promoter. Location: Cytoplasm; Nucleus (UniProt). Locus 19q13.2 (HGNC).
- Where found: Non-Hodgkin lymphoma: Open Targets association 0.51 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 2 cohorts (MLYM, NHL); Diffuse large B-cell lymphoma: CIViC evidence names this disease; IntOGen driver in 2 cohorts (DLBCLNOS)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:9213: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9213
- UniProt P09086: https://www.uniprot.org/uniprotkb/P09086/entry
- NCBI Gene 5452: https://www.ncbi.nlm.nih.gov/gene/5452
- Ensembl ENSG00000028277: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000028277

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/pou2f2.json